
Sign up to save your podcasts
Or


CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week's podcast.
By Medscape4.9
862862 ratings
CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week's podcast.

1,877 Listeners

321 Listeners

549 Listeners

701 Listeners

504 Listeners

167 Listeners

14 Listeners

17 Listeners

3,374 Listeners

138 Listeners

1,150 Listeners

65 Listeners

518 Listeners

367 Listeners

61 Listeners

25 Listeners

8 Listeners

260 Listeners

437 Listeners

270 Listeners